Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs
The drugs of programmed cell death 1 and its ligand 1 immune checkpoint inhibitors have ushered in a new era of anti-tumor immunotherapy, which has shown outstanding efficacy in some tumors, such as Hodgkin lymphoma, but there is still low response rate in some kinds of tumors. In recent years, bispecific antibodies prepared by cell fusion, recombinant DNA, protein engineering and other technologies can specifically bind two antigens or epitopes at the same time or successively, play a synergistic role in tumor treatment, can effectively inhibit tumor immune escape, and improve the effect of anti-tumor treatment has become...
Source: Chinese Journal of Lung Cancer - September 20, 2022 Category: Cancer & Oncology Source Type: research
Low-dose Spiral Computed Tomography in Lung Cancer Screening
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. The low early diagnosis rate and poor prognosis of patients have caused serious social burden. Regular screening of high-risk population by low-dose spiral computed tomography (LDCT) can significantly improve the early diagnosis rate of lung cancer and bring new opportunities for the diagnosis and treatment of lung cancer. In recent years, LDCT lung cancer screening programs have been carried out in many countries around the world and achieved good results, but there are still some controversies in the selection of screening s...
Source: Chinese Journal of Lung Cancer - September 20, 2022 Category: Cancer & Oncology Source Type: research
Application of Immune Checkpoint Inhibitors in EGFR Mutant
Advanced Non-small Cell Lung Cancer
In recent years, immune checkpoint inhibitors (ICIs) have greatly improved the survival rate of non-small cell lung cancer (NSCLC) patients without driver mutation. Compared with wild-type tumors, tumors with epidermal growth factor receptor (EGFR) mutations have greater heterogeneity in immune microenvironment characteristics such as programmed cell death ligand 1 (PD-L1) and tumor mutational burden (TMB). Whether ICIs is suitable for NSCLC patients with EGFR mutation has been controversial. Clinical studies have shown that immunomonotherapy has no significant effect on patients with EGFR mutant NSCLC. ICIs combined with ...
Source: Chinese Journal of Lung Cancer - September 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Circulating Tumor DNA in Non-small Cell Lung Cancer
This article mainly describes the application and research progress of ctDNA in different stages of clinical diagnosis and treatment of non-sma ll cell lung cancer .
DOI: 10.3779/j.issn.1009-3419.2022.102.35 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - September 20, 2022 Category: Cancer & Oncology Source Type: research
Association of CDH1, FANCB and APC Gene Polymorphisms
with Lung Cancer Susceptibility in Chinese Population
This study intends to investigate the relationship between SNPs of CDH1, FANCB, APC genes and lung cancer genetic susceptibility. Methods The case-control study design was used. We collected blood samples from 270 lung cancer cases in the Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, as well as blood samples from 445 healthy volunteers as controls, and extracted genomic DNA for genotyping using the Taqman ® SNP genotyping kit. The distribution of three SNP loci of CDH1 gene rs201141645, FANCB gene rs754552650 and APC gene rs149353082 in Chinese population was analyzed. Chi-square test and...
Source: Chinese Journal of Lung Cancer - September 20, 2022 Category: Cancer & Oncology Source Type: research
Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
Background and objective: Epidermal growth factor receptor (EGFR) mutations are often associated with non-EGFR genetic alterations, which may be a reason for the poor efficacy of EGFR tyrosine kinase inhibitors (TKIs). Here we conducted this study to explore whether EGFR-TKIs combined with chemotherapy would benefit advanced lung adenocarcinoma patients with both sensitive EGFR mutation and concomitant non-EGFR genetic alterations.
Materials and methods: Cases of advanced lung adenocarcinoma with EGFR mutation combined with concomitant non-EGFR genetic alterations were retrospectively collected. And the patients were re...
Source: Chinese Journal of Lung Cancer - September 20, 2022 Category: Cancer & Oncology Source Type: research
Efficacy Analysis of High-flow Nasal Oxygen Therapy in Patients
Accepting Single-port Video-assisted Thoracoscopic Lobectomy
In this study, the superiority-inferiority of different oxygen inhalation methods were compared with high-flow nasal oxygen therapy (HFNO), noninvasive mechanical ventilation (NIMV) and nasal oxygen breath (NOB) in patients with hypoxemia after single-port video-assisted thoracoscopic (VATS) lobectomy, and the clinical efficacy of HFNO in these patients was further investigated. Methods A total of 180 patients from the Second Affiliated Hospital of Soochow University in China with hypoxemia who accepting single-port VATS lobectomy from June 2021 to March 2022 were randomly divided into three groups (n=60), which were treat...
Source: Chinese Journal of Lung Cancer - September 20, 2022 Category: Cancer & Oncology Source Type: research
Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib
Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wide spectrum of multiple resistance mutations within the ALK domain detected during crizotinib and 2nd generation ALK TKI treatment. Lorlatinib is generally well-tolerated with unique adverse drug reaction/adverse event, including hyperlipidemia and central nervous system effects, which are mostly mild to moderate severity and ma...
Source: Chinese Journal of Lung Cancer - August 24, 2022 Category: Cancer & Oncology Source Type: research
Application and Research Progress of Video Double-lumen Tube in Thoracic Surgery
This article reviews the application and research progress of VDLT in thoracic surgery.
DOI: 10.3779/j.issn.1009-3419.2022.101.35 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Acquired Resistance Mediated by MET Amplification
in Advanced Non-small Cell Lung Cancer
Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in overcoming this molecularly defined acquired resistance. Emerging data also demonstrate MET amplification as a resistance driver to TKIs-treated anaplastic lymphoma kinase (ALK)-, RET-, and ROS1-fusion NSCLC. Here, we review the literature on recent research progress of MET amplification as a resistance driver to targeted therapy in...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress on the Application of Liquid Biopsy in the Diagnosis
and Treatment of Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a malignant tumor with strong invasiveness and high mortality. It has the characteristics of easy metastasis, fast growth, high degree of malignancy and strong invasiveness. The prognosis of patients is generally poor. The current clinical diagnosis of SCLC is mainly based on tissue biopsy, which is invasive, long cycle time and high cost. In recent years, liquid biopsy has been gradually applied because of its non-invasive, comprehensive and real-time characteristics that traditional tissue biopsy does not have. The main detection objects of liquid biopsy include circulating tumor DNA (ctD...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research
Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review
The follow-up treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation after drug resistance to EGFR-tyrosine kinase inhibitors (TKIs) have become a hotspot and difficulty at present. Immune checkpoint inhibitors (ICIs) therapy is a new and important choice for these patients, but many studies have shown unsatisfactory efficacy. However, some domestic and foreign studies have shown that ICIs combination therapy is still effective in some patients with positive driver genes and drug resistance after targeted therapy. So, in the era of immunotherapy, what ar...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research
A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma
This article is a review on the research progress of the above pathological high-risk factors and the role of adjuvant chemotherapy in patients with pathological high-risk factors in stage IA lung adenocarcinoma.
DOI: 10.3779/j.issn.1009-3419.2022.101.30 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research
Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated
Advanced Non-small Cell Lung Cancer
Lung cancer is one of the leading causes of cancer-related morbidity and mortality. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have become the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Unfortunately, drug resistance is inevitable in most cases. EGFR-TKI combined with angiogenesis inhibitors is a treatment scheme being explored to delay the therapeutic resistance, which is called “A+T treatment”. Several clinical trials have demonstrated that the A+T treatment can improve the progression free survival (PFS) of the NSCLC patients. However, compared to EGFR...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research
Analysis of Clinicopathologic Features of 9 Cases of
SMARCA4-deficient Non-small Cell Lung Cancer
Conclusion SMARCA4-dNSCLC is a rare subtype of lung cancer with complex and diverse pathological morphology. The characteristic of immunohistochemical phenotype can assist in the diagnosis.
DOI: 10.3779/j.issn.1009-3419.2022.102.27 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research
